Results 11 to 20 of about 29,283 (270)

Circulating Tumor DNA (ctDNA) in Kidney Cancer: A Narrative Review

Société Internationale d’Urologie Journal, 2023
Circulating tumor DNA (ctDNA) has been investigated as a potential noninvasive biomarker for disease prognostication, monitoring, and treatment selection in various tumor types, including renal cell carcinoma (RCC). In this narrative review,
Wesley Yip, A. Ari Hakimi
doaj   +2 more sources

Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels [PDF]

Blood Advances
Abstract Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77 DLBCL cases with both ctDNA and tissue biopsy, a 95.8% concordance rate in molecular cluster assignment
Riccardo Moia, Donatella Talotta, Lodovico Terzi Di Bergamo, Mohammad Almasri, Riccardo Dondolin, Matin Salehi, Chiara Cosentino, Roberta Soscia, Irene Della Starza, Alessio Bruscaggin, Annalisa Andorno, Francesca Mercalli, Stefania Cresta, Riccardo Bomben, Tamara Bittolo, Filippo Vit, Pietro Bulian, Antonella Zucchetto, Riccardo Bruna, Giulia Maria Rivolta, Mattia Schipani, Eleonora Secomandi, Sreekar Kogila, Matteo Bellia, Samir Mouhssine, Jana Nabki, Bashar Al Deeban, Joseph Ghanej, Luca Cividini, Nawar Maher, Federica Melle, Giovanna Motta, Monica Leutner, Angela Lorenzi, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Clara Deambrogi, Silvia Rasi, Luigi Petrucci, Renzo Luciano Boldorini, Alice Di Rocco, Ilaria Del Giudice, Michele Spina, Stefano Palazzolo, Fabio Canal, Vincenzo Canzonieri, Maurizio Martelli, Stefano Pileri, Valter Gattei, Robin Foà, Davide Rossi, Gianluca Gaidano   +51 more
core   +7 more sources

The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST [PDF]

Clinical Cancer Research
Abstract Purpose: Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established. This study evaluates our recently proposed ctDNA-RECIST.
Mette M. Steiniche, Sidsel C. Lindgaard, Inna M. Chen, Julia S. Johansen, Rikke F. Andersen, Torben F. Hansen, Lars H. Jensen, Louise S. Rasmussen, Malene W. Johansen, Morten Ladekarl, Anders K.M. Jakobsen, Karen-Lise G. Spindler   +11 more
openaire   +9 more sources

The Landscape of ctDNA in Appendiceal Adenocarcinoma

Clinical Cancer Research
Abstract Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adenocarcinoma relative to common tumors.
Michael G. White, Mohammad A. Zeineddine, Eleanor A. Fallon, Fadl A. Zeineddine, Julia Dansby, Saikat Chowdhury, Nicholas Hornstein, Abdelrahman Yousef, Mahmoud Yousef, Neal Bhutiani, Yue Gu, Bryan Kee, Arvind Dasari, Michael J. Overman, Kanwal Raghav, Scott Kopetz, Abhineet Uppal, Melissa Taggart, Timothy Newhook, Keith Fournier, Beth Helmink, Leylah M. Drusbosky, John Paul Shen   +22 more
openaire   +3 more sources

ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal

Current Oncology
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies due to late diagnosis and limited treatment options. Circulating tumor DNA (ctDNA) is a promising, minimally invasive biomarker that could improve the clinical outcomes of patients with PDAC by enabling early disease detection, minimal residual disease (MRD) assessment ...
Ojha, Sujata, Sessions, William, Zhou, Yuhang, Aung, Kyaw L.   +3 more
openaire   +3 more sources

ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception [PDF]

Exploration of Targeted Anti-tumor Therapy
Endocrine resistance in estrogen receptor-positive (ER+) breast cancer has undergone a fundamental reconceptualization over the past decade. The discovery that activating mutations in the ESR1 gene encoding ERα emerge under aromatase inhibitor (AI ...
Thais Martinez, Samantha Wegner, Hisham F. Bahmad   +2 more
doaj   +2 more sources

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA [PDF]

, 2023
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy1. The study of large patient cohorts incorporating longitudinal plasma sampling and extended follow-up is required to ...
Moore, David A, Stahl, Josh, Johnson, Laura, Daber, Robert D, Veeriah, Selvaraju, Martínez-Ruiz, Carlos, Stetson, Daniel, Hiley, Crispin T, Riley, Joan, Barrett, J Carl, Weiss, Jakob, Patel, Akshay J, Black, James RM, McGranahan, Nicholas, TRACERx, Consortium, Licon, Abel, Hackshaw, Allan, Chesh, Adrian, Gomes, Fabio, Frankell, Alexander M, Swanton, Charles, Shahpurwalla, Aamir, Chaunzwa, Tafadzwa L, Huebner, Ariana, Jamal-Hanjani, Mariam, Puttick, Clare, Litchfield, Kevin, Aerts, Hugo JWL, Lim, Emilia L, Bye, Hannah, Kortlever, Roderik M, Biswas, Dhruva, Karasaki, Takahiro, Abbosh, Christopher, Cook, Daniel E, Watkins, Thomas BK, Roberts, Paula, Kisistok, Judit, Odell, Aaron, Manzano, Elizabeth, Harrison, Thomas, Moreau, Mike, Godin-Heymann, Nadia, Bakir, Maise Al, Grigoriadis, Kristiana, Evan, Gerard I, Garnett, Aaron, Birkbak, Nicolai J, Pich, Oriol, Schroeder, Morgan R, Hodgson, Darren, Ward, Sophia, Shaw, Jacqui A, L'Hernault, Anne, Carey, Nicolas   +54 more
core   +10 more sources

ctDNA in the reading room: A guide for radiologists

European Journal of Radiology
Liquid biopsy with sequencing of circulating tumor DNA (ctDNA) is a minimally invasive method for sampling body fluids and offers a promising alternative to tissue biopsies that involve greater risks, costs, and time. ctDNA not only identifies actionable targets by revealing unique molecular signatures in cancer, but also may assess treatment response,
Hayes, Pearce, Yu-Cherng, Chang, Marcia C, Javitt, Jashodeep, Datta, Agustin, Pimentel, Steven, Bialick, Peter J, Hosein, Francesco, Alessandrino   +7 more
openaire   +3 more sources

ctDNA as a biomarker of progression in oesophageal adenocarcinoma [PDF]

ESMO Open, 2021
Abstract Background: The incidence of oesophageal adenocarcinoma (OAC) is rapidly increasing and despite improvements in treatment, the five-year survival rate remains poor. Prognostic biomarkers that address the genomic heterogeneity in this highly complex disease will aid the development of precision therapeutics and improve patient survival.
Vanessa F. Bonazzi, Lauren G. Aoude, Sandra Brosda, James M. Lonie, Kalpana Patel, Julia J. Bradford, Lambros T. Koufariotis, Scott Wood, B. Mark Smithers, Nicola Waddell, Andrew P. Barbour   +10 more
openaire   +4 more sources

Liquid biopsy in CNS tumors: Current status & future perspectives

Indian Journal of Pathology and Microbiology, 2022
Precise classification of central nervous system (CNS) malignancies is vital for the treatment and prognostication. Identification of noninvasive markers can be of importance to guide treatment decisions and in monitoring treatment response.
Nuzhat Husain, Adil Husain, Sridhar Mishra, Pallavi Srivastava   +3 more
doaj   +1 more source